A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.Iyer SP et al. Br J Haematol. 2014 Aug 19. doi: 10.1111/bjh.13056. [Epub ahead of print].Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis.Frediani…
DetailsSubclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. Kosturakis AK et al. J Clin Oncol. 2014 Aug 25. pii: JCO.2013.54.5418. [Epub ahead of print]. Hepatitis B virus reactivation in multiple myeloma patients receiving bortezomib-containing regimens followed by autologous stem cell transplantation. Li J et al. Leuk…
DetailsUpdate of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Mateos MV et al. Blood. 2014 Aug 7. pii: blood-2014-05-573733. [Epub ahead of print]. Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood…
DetailsThese updated guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the diagnosis and management of myeloma patients. They should be read in conjunction with the BCSH Guidelines on the supportive care of myeloma patients. Bird et al.…
DetailsThese guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the supportive care of myeloma patients and should be read in conjunction with the BCSH Guidelines for the diagnosis and management of myeloma.
This paper, written by an expert panel on behalf of the European Myeloma Network, reviews the available evidence and provides recommendations for the management of newly diagnosed myeloma patients.
This paper, written by an expert panel on behalf of the International Myeloma Working Group, addresses the need for new uniform response criteria for myeloma patients.
This article, produced by the International Myeloma Working Group, reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of transplantation-eligible myeloma patients.
This paper provides an update to the first guideline published in 2005 by the International Myeloma Working Group on the management of myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation. It includes recommendations on the diagnosis and treatment of these patients together with the management of side-effects of treatment.
This paper, written by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the available evidence and provides recommendations for the management of myeloma-related bone disease. It also includes expert consensus to propose additional recommendations where there were insufficient published data.